Medical News Today: MDS symptoms: What are the signs of pre-leukemia?

MDS, or myelodysplastic syndrome, refers to a group of blood cancers. In this article, learn about the symptoms and complications of this disease.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Related Links:

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) developing in persons exposed to DNA-damaging agents for a prior cancer are often referred to as treatment- or therapy-related myeloid neoplasms (t-MN)[1,2]. t-MN constitute approximately 10-20% of all cases of AML and MDS[3], a proportion that may increase in the future with an increasing prevalence of cancer survivors[4,5]. Hematopoietic cell transplants (HCT) use high doses of drugs and/or ionizing radiations and can also lead to t-MN[6,7].
Source: Leukemia Research - Category: Hematology Authors: Source Type: research
Abstract The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could eliminate MCL cells at the first strike, reduce the chance for secondary resistance, and cause long-term remissions. If optimized, it could become an alternative to cure MCL. The key is the intensity of front-line therapy. Both the Nordic 2 and the MD Anderson Cancer Center HCVAD trials, with follow-up times greater than 10 years, achieved long-term survivals exceeding 1...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Exp Clin Cancer Res Source Type: research
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research
The majority of blood cancers occur in the elderly. This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists. In this review, we first define frailty and its relevance for patients with hematologic malignancy. Next, we review current data regarding the effect of domains of frailty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma. Finally, after presenting assessment and treatment options for the practicing hematolo...
Source: Blood - Category: Hematology Authors: Tags: Free Research Articles, Myeloid Neoplasia, Lymphoid Neoplasia, Review Articles, Review Series, Clinical Trials and Observations Source Type: research
ConclusionsThe burden of tAML/tMDS in Victoria is likely to be underestimated. Linkage between VCR and clinical registries is needed to provide more accurate insights.
Source: Internal Medicine Journal - Category: Internal Medicine Authors: Tags: Original Article Source Type: research
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Micro-Abstract Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Are the myeloid malignancies leading the way, based on our ability to easily obtain tumor tissue and success in CML, or are they following, given the use of multi-gene panels to treat upfront advanced lung cancer and the remarkable outcomes using check point inhibitors to treat formerly intractable solid tumors? Past achievements in the leukemias have been impressive but incomplete. In chronic phase CML we have essentially curative treatments; in myeloproliferative neoplasms we know the mutations but possess only partially effective therapies; and in myelodysplastic syndrome many mutations have been described but effective...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Uncontrolled dyspnea is terrifying for patients and has a negative effect on quality of life (QOL) (Gupta, Lis,&Grutsch, 2007). Fatigue (92%), dyspnea (63%), and pain (55%) have been reported as the three most prevalent symptoms for patients diagnosed with higher risk myelodysplastic syndromes (MDS) (Efficace et al., 2015). Dyspnea and associated symptoms in advanced cancer are not adequately treated due to limited research and understanding of the experience (Twaddle et al., 2007).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Cancer survivors may develop a second cancer as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) and this has been an emerging problem for acute promyelocytic leukemia (APL) patients in complete remission (CR).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Umang Patel, Rajyalakshmi Luthra, L. Jeffrey Medeiros, Keyur P. Patel The classification and risk stratification of myeloid neoplasms, including acute myeloid leukemia, myelodysplastic syndromes, myelodysplastic syndromes/myeloproliferative neoplasms, and myeloproliferative neoplasms, have increasingly been guided by molecular genetic abnormalities. Gene expression analysis and next-generation sequencing have led to the ever increasing discovery of somatic gene mutations in myeloid neoplasms. Mutations have been ide...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Health | Learning | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Universities & Medical Training